Enantis is humbled and beyond excited to win the BRKTHRU VOICES award by The Estée Lauder Companies Inc. Out of over a hundred innovative companies, Enantis emerged victorious. This remarkable recognition propels us forward, empowering us to forge vital connections within the cosmetics industry and propel our groundbreaking FGF2-STAB product into the market.

This win comes as an unexpected yet immensely welcome validation of our efforts, especially considering we have just launched our first cosmetics product. It signifies not only our dedication to innovation (drum roll for Terézia Ikrényiová, MSc. and Jan Herudek in our cosmetics team) but also the industry’s recognition of our potential to drive transformative change.

It has been nice to meet the other finalists and we hope there will be a chance to collaborate further – AM BioTech – Ascension Medical Biotechnology, Oriel Marine Extracts, SETHIC INNOVATIONS and SupadElixir.

Thank you to The Estée Lauder Companies Inc. and in-cosmetics Global for this incredible honor. This award fuels our determination to continue pushing boundaries and making a lasting difference in the cosmetics industry. 🚀

We’re thrilled to announce that Enantis will be participating at InCosmetics 2024 in Paris, 16-18th April! 🇫🇷
Join us at Booth 1A35 as we unveil our latest innovation: the FGF2-STAB® product for cosmetics use.
Our team has been hard at work developing this groundbreaking product, leveraging the power of FGF2 to revolutionize the cosmetics industry. With its unparalleled benefits, FGF2-STAB® promises to redefine skincare and beauty standards.
Don’t miss this opportunity to experience the future of cosmetics firsthand!
Visit us at InCosmetics 2024 to learn more about FGF2-STAB® and discover how it can elevate your cosmetics products.

See you there!

Exciting News from Enantis!
Our brilliant PhD candidate, Gabin de La Bourdonnaye, has developed a game-changing thermostable FGF21 growth factor 🌡️, soon to join Enantis’ portfolio. Check out the paper here: https://lnkd.in/eFfzBBT8

This novel growth factor has the potential to revolutionize metabolic disease treatment— think obesity, dyslipidemia, and insulin intolerance. Engineered for thermostability, it shows improved pharmacokinetics, allowing for lower dosage and reduced administration frequency, minimizing side effects.

Interested in exploring the potential of thermostable FGF21? Reach out, and we’ll provide more info.

Let’s shape the future of growth factors together! 🚀

We are thrilled to share that our FGF2-STAB® has been granted a patent in India! 🇮🇳
As we celebrate, we’re also expanding our patent portfolio to cover more territories. Stay tuned for more innovations!

🎉 Fantastic News! 🎉
Enantis has just been granted a US patent for its groundbreaking invention of FGF2-STAB®. This engineered protein is a true game-changer – it’s a thermostable powerhouse 🌡️🔥, boasting a mind-boggling stability that’s 50-times greater at 37°C than that of wild type FGF2. 💪
This opens up a world of possibilities in the realm of biotechnology, with potential applications that can revolutionize research, therapies, cosmetics, cultured meat and beyond. 🌐🔬
A huge round of applause to our brilliant team and also to Masaryk University team for pushing the boundaries of what’s possible in science and biotech! 🧬

#patentgranted #USpatent #brnoregion #IP

💡Join us once again as we unveil the next chapter in our “Meet Enantis” series with issue nine!💡

Our plan is to introduce all the brilliant minds that fuel Enantis’ innovation, as our company is not just about business – it’s about the people who make the magic happen!

This time, we’re thrilled to introduce Jan Vilím, our Head of Production and R&D 🧪🧬, and offer you an insightful interview that gives a glimpse into his role and experiences at Enantis. Delve into the world of production and research as Jan shares his journey, thoughts, and passions.

Meet Enantis series is a unique opportunity to get to know the people who drive Enantis’ innovation on a personal level. Stay tuned for more candid conversations that shed light on the inner workings of our company and the individuals who contribute to its success.

INTERVIEW HERE

#biotech #production #HR #randd #brnoregion

FGF2-STAB®: Clinically Proven Cosmetics Ingredient!

Enantis is thrilled to share some amazing news with you! FGF2-STAB®, a groundbreaking cosmetics ingredient, has been clinically and dermatologically tested and proven effective. It was shown that it retains skin hydration, reduces wrinkles, and softens the skin.

FGF2-STAB® underwent rigorous testing, showing impressive results. Participants experienced improved skin hydration leading to visible wrinkle reduction and softer skin. What’s more, FGF2-STAB® is safe to use, with no cytotoxicity or skin irritation observed during testing.

This verification of FGF2-STAB® as an effective cosmetics ingredient is a game-changer in achieving optimal skin health. This revolutionary product is now available for supply and licensing as an innovative cosmetics ingredient. We will be happy to hear from you if you want to give it a try in your cosmetics formulation.

Exciting times ahead!

We are happy to announce an open call for a PhD fellowship for the Marie Skłodowska-Curie European Doctoral Network BiocatCodeExpander.

Are you interested in being part of an innovative biotech team? Join Enantis and play a role in our exciting project of rational design of growth factors as therapeutically and biotechnologically attractive proteins using incorporation of non-canonical amino acids (NCAA).

More info HERE

📢 Job Opportunity: Bioinformatician Position Available 🧬🔬

We are thrilled to announce an exciting career opportunity for a talented and motivated bioinformatician to join our dynamic team! If you have a passion for bioinformatics, data analysis, and cutting-edge computational techniques, this position is perfect for you.

Join us on this exciting journey of scientific exploration and contribute to advancing our understanding of the intricate complexities of life through bioinformatics. Take the first step towards a rewarding career by applying today!

Please note that the application deadline for this position is 26^th of June 2023.

We look forward to reviewing your application and welcoming you to our team!

Bioinformatician Job advert Enantis

Our FGF2-STAB® has been given an interesting redo by a team of scientists from the University of Wroclaw. They have used our thermostable molecule to create cyclic and dimeric protein variants that might have higher potential in regenerative and cancer medicine. The resulting variants present different effects on the signaling cascade and modulate the pleiotropic effect of FGF2. Proposed applications of these new variants include wound healing – as cyclic FGF2-STAB® is more active and stable, anticancer therapy – as FGF2-STAB®-based drug carrier and also in glucose uptake – for diabetic patients that cannot be treated with insulin.

Have we aroused your interest? Read on…

https://lnkd.in/gxMM43st